Benefits and Complications Following First-Line Treatment with Atezolizumab plus Bevacizumab in a Patient with HCC: a Case Report
Until recently, sorafenib was the only systemic treatment available for patients with advanced hepatocellular carcinoma (HCC) since its approval in 2007. In the IMbrave150 trial, atezolizumab plus bevacizumab, as first-line therapy, demonstrated improvement in overall survival (OS) and progression-f...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2022-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000//hbT.OH.2022.11.064 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Until recently, sorafenib was the only systemic treatment available for patients with advanced hepatocellular carcinoma (HCC) since its approval in 2007. In the IMbrave150 trial, atezolizumab plus bevacizumab, as first-line therapy, demonstrated improvement in overall survival (OS) and progression-free survival (PFS) in patients with unresectable HCC compared with sorafenib. Based on these results, this combination is recommended as a standard of care for treatment-naïve patients with advanced HCC and Child-Pugh A cirrhosis.
Earlier, we presented a review of systemic treatments for advanced HCC.^1^ Here, we reported the case of a 61-year-old patient with excellent response to the treatment with atezolizumab plus bevacizumab, despite a serious complication. |
|---|---|
| ISSN: | 2673-2092 2673-2106 |